Pharmacokinetics of evocalcet in secondary hyperparathyroidism patients receiving hemodialysis: first-in-patient clinical trial in Japan
Takashi Shigematsu,1 Ryutaro Shimazaki,2 Masafumi Fukagawa,3 Tadao Akizawa4 On behalf of the Evocalcet Study Group 1Department of Nephrology, Wakayama Medical University, Wakayama, Japan; 2R&D Division, Kyowa Hakko Kirin Co., Ltd., Chiyoda-ku, Tokyo, Japan; 3Department of Internal Medicine,...
Main Authors: | Shigematsu T, Shimazaki R, Fukagawa M, Akizawa T |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-09-01
|
Series: | Clinical Pharmacology: Advances and Applications |
Subjects: | |
Online Access: | https://www.dovepress.com/pharmacokinetics-of-evocalcet-in-secondary-hyperparathyroidism-patient-peer-reviewed-article-CPAA |
Similar Items
-
Long-term treatment of evocalcet in hemodialysis patients with secondary hyperparathyroidism: a five-year prospective cohort study in 147 Japanese patients
by: Nobuo Nagano, et al.
Published: (2024-03-01) -
Еffectiveness of long-term cinacalcet administration in hemodialysis patients with secondary hyperparathyroidism: A prospective, historically controlled study
by: O.M. Loboda, et al.
Published: (2021-12-01) -
Efficacy and Safety of Evocalcet Evaluated by Dialysate Calcium Concentration in Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis
by: Shigematsu T, et al.
Published: (2020-05-01) -
Pharmacokinetics, Pharmacodynamics, and Safety of Evocalcet (KHK7580), a Novel Calcimimetic Agent: An Open-Label, Single- and Multiple-Dose, Phase I Trial in Healthy Chinese Subjects
by: He X, et al.
Published: (2024-02-01) -
Novel treatment options for secondary hyperparathyroidism in end-stage kidney disease patients on hemodialysis therapy
by: Liudmila Y. Rozhinskaya, et al.
Published: (2017-05-01)